Association between gene polymorphisms and clinical features in idiopathic thrombocytopenic purpura patients

Rezaeeyan, Hadi; Jaseb, Kaveh; Alghasi, Arash; Asnafi, Ali Amin; Saki, Najmaldin

doi:10.1097/mbc.0000000000000646

Cited by 21 publications

(12 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 For example, SNPs in some inflammatory cytokines may be associated with thrombocytopenia in immune thrombocytopenic purpura (ITP) and leukemia. 7,8 In this regard, we enumerate some of the most common cytokine SNPs that can be associated with thrombocytopenia in solid tumors.…”

Section: Cytokine Polymorphism-induced Thrombocytopenia In Solid Tumorsmentioning

confidence: 99%

Thrombocytopenia in solid tumors: Prognostic significance

et al. 2019

View full text Add to dashboard Cite

Solid tumors are a heterogeneous group of malignancies that result from out-of-control proliferation of cells. Thrombocytopenia is a common complication among patients with solid tumors that predispose them to bleeding disorders. The aim of this review article is to investigate the underlying mechanisms of the risk and incidence of thrombocytopenia in solid tumors. It can be argued that thrombocytopenia is a poor prognostic factor in solid tumors that can result from several factors such as polymorphism and mutation in some transcription factors and cytokines involved in megakaryocytic maturation or from the adverse effects of treatment. Therefore, an understanding of the exact mechanism of thrombocytopenia pathogenesis in each stage of solid tumors can help in developing therapeutic strategies to decrease bleeding complications in these malignancies.

show abstract

Section: Cytokine Polymorphism-induced Thrombocytopenia In Solid Tumorsmentioning

confidence: 99%

Thrombocytopenia in solid tumors: Prognostic significance

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The most common drug for the treatment of ITP is glucocorticoids, but some patients with ITP are insensitive or intolerant to glucocorticoids, which causes ITP patients to become refractory after glucocorticoid treatment (13). With the advancement of modern medicine, refractory ITP can be alleviated, but it is still difficult to achieve full rehabilitation, the incidence is high and the treatment cycle is long (14,15). Therefore, the use of proper drugs for timely treatment is the key to control the deterioration of the disease (16).…”

Section: Discussionmentioning

confidence: 99%

Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura

Wang

Sun

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura (ITP) were investigated. We retrospectively analyzed 249 patients with refractory ITP who were admitted to Qingdao Hiser Medical Group between March 2013 and March 2017. Curative effects of patients treated with rituximab, cyclophosphamide, and combination therapy were observed and the changes of platelet count, PA IgG, and lymphocyte CD20 before and after treatment, as well as the incidence of adverse reactions after treatment, were compared. There was no significant difference in the expression of lymphocyte CD20, PA IgG and platelet count among the three groups of refractory ITP patients before treatment (P>0.05). After treatment, the expression levels of CD20 and PA IgG in lymphocytes were significantly downregulated, and platelet counts significantly increased in the three groups (P<0.05). After treatment, CD20 and PA IgG levels in combined therapy group were significantly lower, and platelet count was significantly higher, than those in the rituximab and cyclophosphamide groups (P<0.05). Also, after rituximab treatment, the expression levels of CD20 and PA IgG in lymphocytes were significantly lower than those in cyclophosphamide group (P<0.05), and platelet count was higher than that in cyclophosphamide group (P<0.05). After treatment, the total effective rate in combined therapy group was higher than that in the rituximab and cyclophosphamide group (P<0.05). Total effective rate of rituximab group was significantly higher than that of cyclophosphamide group (P<0.05). The incidence of adverse reactions in combined therapy group was 14.29% (12/84), which was significantly lower than that in cyclophosphamide group (40.70%, 35/86, P<0.05) and rituximab group (29.11%, 23/79, P<0.05). The application of rituximab combined with cyclophosphamide in the treatment of refractory ITP can improve patients clinical symptoms. The efficacy of this technique is promising with no serious adverse reactions. This technique should be popularized in clinical practice.

show abstract

“…Immune thrombocytopenic purpura is an autoimmune disorder that is associated with the peripheral destruction of platelets by autoantibodies against platelet GPs . The pathophysiology of ITP is heterogeneous and genetic background (such as the percentage of polymorphisms in immune system‐related genes), as well as aberrant expressions of some chemokine receptors and micro‐RNAs alongside antiplatelet antibodies, may play a crucial role in predisposition to ITP and even response to treatment . Moreover, impairment of the number and function of different immune cells can play an important role in the initiation and prolongation of ITP .…”

Section: Discussionmentioning

confidence: 99%

Cellular expression of CD markers in immune thrombocytopenic purpura: implications for prognosis

Behzad

Asnafi

Jalalifar

et al. 2018

APMIS

Self Cite

View full text Add to dashboard Cite

Immune thrombocytopenic purpura (ITP) is an autoimmune bleeding disorder associated with platelet destruction. Abnormalities in frequency and function of different immune cells can play a crucial role in this disease. The aim of this study was to evaluate the prognostic value of CD markers' expressions by immune cells in ITP. Peripheral blood samples were collected from 25 ITP patients before and after treatment. The expression of CD markers was evaluated by flow cytometry technique. The expression of CD38 and CD56 was significantly lower before treatment than after it (p = 0.025 and p = 0.036, respectively). Furthermore, a positive correlation was found between CD38 expression with platelet count before (r = 0.496, p = 0.012) and after treatment (r = 0.404, p = 0.045). No significant relationship was found between this marker and platelet count while CD4 expression was higher before treatment than after it (p = 0.002). In conclusion, CD38 may have independent prognostic value in ITP and we suggest that it can be a prognostic marker for this disease.

show abstract

Association between gene polymorphisms and clinical features in idiopathic thrombocytopenic purpura patients

Cited by 21 publications

References 65 publications

Thrombocytopenia in solid tumors: Prognostic significance

Thrombocytopenia in solid tumors: Prognostic significance

Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura

Cellular expression of CD markers in immune thrombocytopenic purpura: implications for prognosis

Contact Info

Product

Resources

About